Antagonists targeting CD30 have not yet been developed although CD30-mediated signaling including NF-κB pathway whose aberrant activation may contribute on a variety of human diseases, including inflammatory and autoimmune diseases [8]. The gene discussed is TNFRSF8; the disease is autoimmune disease.